Direkt Links to important GMP Blood Product Guidelines

21 CFR Part 606 Current Good Manufacturing Practice for Blood and Blood Components

US GMP Requirements for manufacturers of blood and blood components

more

PIC/S GMP Guide for Blood Establishments (PE 005-3) Sept 2007

This document applies to blood and apheresis establishments relating to the collection, preparation, storage, dispatch, quality control and quality assurance of human blood and blood components.

more

FDA Guidance for Industry; Blood Establishment Computer Systems Validation in the User's Facility

FDA, is issuing this guidance to assist you, blood establishments, in developing a blood establishment computer system validation program, consistent with recognized principles of software validation, quality assurance, and current good software engineering practices.

more

Eudralex Volume 3 GUIDELINE ON EPIDEMIOLOGICAL DATA ON BLOOD TRANSMISSIBLE INFECTIONS

The requirement to collect epidemiological data on blood transmissible infections is intended to obtain information on the infection risk in a specific donor population and is thus an essential part of the measures taken to ensure an adequate selection of donors of blood and plasma. The purpose of these data is to characterise the donor population with respect to infection risk, and to allow comparison of risks between donor populations of individual collection centres.

more

FDA Guidance for Industry Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products

Recommendations related to Donor deferral to minimise transmission risk of HIV via blood and blodd components

more

FDA Guidance for Industry: Informed Consent Recommendations for Source Plasma Donors Participating in Plasmapheresis and Immunization Programs

This guidance provides recommendations to blood establishment, for obtaining written informed consent from a prospective Source Plasma donor participating in a plasmapheresis program or an immunization program

more

FDA Guidance for Industry: Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Blood and Blood Components

This guidance provides blood establishments that collect blood and blood components intended for transfusion or for further manufacture (referred to as "manufacturers" or "you") with advice on reporting to the Food and Drug Administration (FDA) a manufacturing change consisting of the implementation of a standardized full-length donor history questionnaire and accompanying materials (DHQ documents).

more

FDA Guidance for Industry: Biological Product Deviation Reporting for Blood and Plasma Establishments

Recommendations for Reporting of BPD (Biological Product Deviation)

more

FDA Guidance for Industry: Recognition and Use of a Standard for Uniform Blood and Blood Component Container Labels

Requirements of standard uniformed labeling of Blood and Blodd componenets containers

more

FDA Guidance for Industry: Amendment (Donor Deferral for Transfusion in France Since 1980) to “Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob

Guidance intended to amend the "Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products" (CJD/vCJD guidance), dated January 2002 (Ref. 1), by adding a donor deferral recommendation for donors who have received a transfusion of blood or blood components in France since 1980.

more

GMP Conferences by Topics

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information

OK